China Pharmaceutical University

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Haiping Hao

Hong Wang

Sheng Jiang

Hequan Yao

Yiwu Yao

Dong Chen

Jiyu Zhou

Ningning Huang

Yitong Guo

Xiaojie Pan

Shuang Cui

Guangji Wang

Peng Yang

Yatao Qiu

Zhengchao Tu

Wenbin Kuang

Kai Yuan

Xiao Wang

A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.

Composition containing sumo inhibitor and application

A heterocyclic urea compound, and specifically discloses an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, which solves the problems of weak curative effect and larger toxic and side effects of existing immunological therapy drugs. The invention further provides a preparation method for an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, and an application of the indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound or a pharmaceutically acceptable salt thereof in preparing drugs for treating or preventing tumors.

Heterocyclic urea compound, and drug composition and application thereof

Growing community of inventors

Nanjing, China

Haiping Hao